New York, USA – November 29, 2021 – CD BioSignal, a US-based life science research product supplier and CRO, recently introduces a comprehensive panel of research solutions covering all aspects of diabetes and metabolism and metabolic disease study to provide the scientific community a better and deeper understanding of metabolic regulation.
Metabolism describes the series of chemical reactions in a living system. The purposes of metabolism are conversion of nutrients to energy and building blocks, and elimination of nitrogenous wastes. The processes of metabolism are tightly controlled by cellular signaling pathways to maintain the metabolic homeostasis of the system. Altered patterns of metabolism are one of the hallmarks of cancer.
Metabolic pathways are a series of chemical reactions of metabolism, which are catalyzed by a sequence of enzymes. However, metabolic signaling pathways refer to the cellular signaling transductions that respond to metabolic state and regulate cellular events to maintain cell and organismal homeostasis. Dysregulation of these pathways is associated with metabolic diseases such as obesity, type 2 diabetes, as well as cancer and aging.
CD BioSignal now provides various solutions for metabolism research, such as regulator identification for identifying gene regulators participating in certain metabolic signaling pathways, regulator characterization for studying the molecular function of certain regulators in metabolic signaling pathways, and mechanism study used for investigating into the mechanism of regulation of certain regulators. More solutions like phenotype analysis, animal model generation, chemical screening, and therapy development are also offered by CD BioSignal.
These new series of solutions can be used for studying metabolic signaling pathway, such as the insulin signaling pathway, mTOR pathway, and AMPK pathway. For example, the insulin signaling pathway, which is signaling transduction that regulates glucose homeostasis through control of glucose and lipid metabolism. When insulin is released by pancreatic beta cells in response to elevated levels of nutrients, it binds to the insulin receptor, which activates the signaling transduction and leads to cellular processes that promote the uptake of glucose, fatty acids, and amino acids.
Insulin resistance, or cells fail to respond normally to insulin, is the underlying cause of type 2 diabetes. It also has a strong correlation with neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s disease and Huntington’s disease. With advanced technologies and dedicated scientists, CD BioSignal now offers research solutions for customers to study the insulin signaling pathway and the related diseases.
“CD BioSignal is committed to fulfilling all your demands in the research of signaling pathways. We provide high-quality reagents and comprehensive solutions to support your innovative discoveries. These newly released metabolism related research solutions are cost-effect, high quality and hassle-free, and are accessible to our clients worldwide. We guarantee to deliver our products and results on time.” said Kristy J. Morris, the marketing director at CD BioSignal.
Customers for more information about the diabetes & metabolism solutions, please visit CD BioSignal at https://www.cd-biosignal.com.
About CD BioSignal
CD BioSignal is a trusted research product supplier and CRO based in New York. With high-quality reagents and comprehensive services, CD BioSignal is the one-stop shop devoted to researchers making advancements in signaling pathway studies.